Investing Experience -
Risk Profile -
Followers
65
Following
4
Blog Posts
0
Threads
19,949
Blogs
Threads
Portfolio
Follower
Following
Summary
Total comments
19,949
Past 30 days
23
Past 7 days
3
Today
0
User Comments
Stock
2020-09-07 18:17 | Report Abuse
China's nationalistic tabloid Global Times reported last month that "the price of the vaccines will not be high."
Every two doses should cost below 1,000 yuan (US$146), the report said, citing Sinopharm's chairman, who told media he has already been injected with one of the candidate vaccines.
China's official Xinhua news agency reported on Monday that another vaccine candidate, developed by Chinese military scientists, can deal with mutations in the coronavirus.
As of last month, at least 5.7 billion doses of the vaccines under development around the world had been pre-ordered.
Stock
2020-09-07 18:16 | Report Abuse
China's nationalistic tabloid Global Times reported last month that "the price of the vaccines will not be high."
Every two doses should cost below 1,000 yuan (US$146), the report said, citing Sinopharm's chairman, who told media he has already been injected with one of the candidate vaccines.
China's official Xinhua news agency reported on Monday that another vaccine candidate, developed by Chinese military scientists, can deal with mutations in the coronavirus.
As of last month, at least 5.7 billion doses of the vaccines under development around the world had been pre-ordered.
Stock
2020-09-07 15:14 | Report Abuse
Although no. of shipment during a specific time frame is only an indicator. It does not represent the absolute sales result in a market.
But, please take note, the decreasing import from supermax happen is at time US ban global top largest Top glove import glove in July. Theoretically, banning gloval largest glove maker since July should translate to significant higher import from other glove maker to substitute absent market share from topglove. But, in contrast, US also reduce significantly glove volume from supermax till now.
Do you think its good news for supermax ?
Some said should compared to last year volume......No, you should compared consecutive volume during covid pandemic time instead of compared last year nil pandemic time. No point to compared glove demand in pandemic vs. non pandemic.
Some said use old data to confuse? but supermax healthcare import is update on weekly basis. The decreasing trend should serve as early warming instead of still fall deep in past record when data should peak demand in May
https://importkey.com/i/supermax-healthcare-inc
Stock
2020-09-07 14:07 | Report Abuse
KUALA LUMPUR: 48 per cent of Malaysians surveyed think a vaccine for Covid-19 would be made available to them by the end of the year.
This makes Malaysians more optimistic than the global average, found an Ipsos survey for the World Economic Forum.
"Malaysia and China are two very confident countries that believe the Covid-19 vaccine will be available by the end of the year while other Western countries have little hope of it," said the market research company.
The survey - Attitude on Covid 19 Vaccine, found that China was the most optimistic at 87 per cent, while most Western countries and Japan were less optimistic about the prospects of a vaccine being found for the novel coronavirus by the end of 2020.
You May Also Like
Even with vaccine, battle against Covid-19 will last years
China Covid-19 vaccine approved - for its military
'Little chance of Covid-19 vaccine by 2021'
Putin: Russia has developed 'first' Covid-19 vaccine
Although the discovery of the vaccine seems to build an excitement, nevertheless almost half of the Malaysians surveyed were concerned about the side effects such a vaccine might leave behind, Ipsos said.
It adds that the survey also found that a third of Malaysians refuse to think that the vaccine would be effective, while a good number of them were optimistic that they would not be at risk from Covid-19 and as such they would not find it necessary to get the shot.
"As countries and companies push against time to release a Covid-19 vaccine, public opinion and acceptability also play an important role in its success.
"Malaysians stand with the emerging economies, in their optimism for an early availability of Covid-19 vaccine.
"Universal and affordable public health care system support Malaysians' confidence in the availability of vaccine for the masses," Managing director of IPSOS Malaysia, Arun Menon said.
He stressed that public authorities should be conscious about the general apprehension on side effects and vaccine effectiveness as potential barriers of adoption.
Stock
2020-09-07 14:07 | Report Abuse
KUALA LUMPUR: 48 per cent of Malaysians surveyed think a vaccine for Covid-19 would be made available to them by the end of the year.
This makes Malaysians more optimistic than the global average, found an Ipsos survey for the World Economic Forum.
"Malaysia and China are two very confident countries that believe the Covid-19 vaccine will be available by the end of the year while other Western countries have little hope of it," said the market research company.
The survey - Attitude on Covid 19 Vaccine, found that China was the most optimistic at 87 per cent, while most Western countries and Japan were less optimistic about the prospects of a vaccine being found for the novel coronavirus by the end of 2020.
You May Also Like
Even with vaccine, battle against Covid-19 will last years
China Covid-19 vaccine approved - for its military
'Little chance of Covid-19 vaccine by 2021'
Putin: Russia has developed 'first' Covid-19 vaccine
Although the discovery of the vaccine seems to build an excitement, nevertheless almost half of the Malaysians surveyed were concerned about the side effects such a vaccine might leave behind, Ipsos said.
It adds that the survey also found that a third of Malaysians refuse to think that the vaccine would be effective, while a good number of them were optimistic that they would not be at risk from Covid-19 and as such they would not find it necessary to get the shot.
"As countries and companies push against time to release a Covid-19 vaccine, public opinion and acceptability also play an important role in its success.
"Malaysians stand with the emerging economies, in their optimism for an early availability of Covid-19 vaccine.
"Universal and affordable public health care system support Malaysians' confidence in the availability of vaccine for the masses," Managing director of IPSOS Malaysia, Arun Menon said.
He stressed that public authorities should be conscious about the general apprehension on side effects and vaccine effectiveness as potential barriers of adoption.
Stock
Stock
Stock
Stock
2020-09-07 14:04 | Report Abuse
Almost half of Malaysians confident vaccine will be available in 2020 — Ipsos
KUALA LUMPUR (Sept 7): Almost half of Malaysians, or 48%, trust that a vaccine will be available to them before the end of the year, ahead of the global average.
In a recent Ipsos survey for the World Economic Forum released recently, China emerged as the most optimistic with a total of 87% while Japan appears to be the most pessimistic with only 22% of its people agreeing to the possibility of a vaccine available to them.
In a statement, Ipsos managing partner Arun Menon said as countries and companies push against time to release a Covid-19 vaccine, public opinion and acceptability play the most important role in its success.
Menon said a universal and affordable public health care system supports Malaysian confidence in the availability of vaccines for the masses.
As a result of respective governments and health authorities’ rapid push for the production of a vaccine for Covid-19, there are increasing and valid doubts over its side effects and effectiveness.
In determining more specificities of the aforementioned, the Ipsos survey also conducted a search on possible reasons Malaysians would not take the vaccine for Covid-19.
The results of the survey show that the top reason is indeed the public’s worry about the vaccine’s potential side effects.
However, the next reason in line, with 36% of the population on board, is the opinion that they are not at risk from Covid-19.
It is notable that Malaysians are much more confident of being free from the risks from Covid-19 as compared to the global average (19%).
The third reason differs from that of the global average as well, which is the disbelief that the vaccine will be effective (29%).
However, even for this reason, Malaysia stands at a slightly higher percentage than the average with a total of 33% of its population believing so.
Menon said public authorities should be conscious about the general apprehension on side effects and vaccine effectiveness as potential barriers of adoption.
https://www.theedgemarkets.com/article/almost-half-malaysians-confident-vaccine-will-be-available-2020-%E2%80%94-ipsos
Stock
2020-09-07 13:50 | Report Abuse
Glove export to US on decreasing trend. The US market peak demand already reached in May, thereafter, already on decreasing demand from supermax.
Please take note, the decreasing import from supermax happen is at time US ban Top glove in July.
Theoretically, US covid case surge up significantly in July til now, and banning glove from top glove since July should translate to significant leap up higher import from other glove maker to substitute absent market share from topglove.
But, in contrast, US also reduce significantly glove volume from supermax till now.
The only justifiable RATIONALE is US glove market also reached Peak demand in last May, and on decreasing trend even after take into account surge in covid case + banning topglove from entry to US since july
https://importkey.com/i/supermax-healthcare-inc
Remark: US is largest import market and US market command highest ASP premium if compared to any other country.
Stock
2020-09-07 13:49 | Report Abuse
Glove export to US on decreasing trend. The US market peak demand already reached in May, thereafter, already on decreasing demand from supermax.
Please take note, the decreasing import from supermax happen is at time US ban Top glove in July.
Theoretically, US covid case surge up significantly in July til now, and banning glove from top glove since July should translate to significant leap up higher import from other glove maker to substitute absent market share from topglove.
But, in contrast, US also reduce significantly glove volume from supermax till now.
The only justifiable RATIONALE is US glove market also reached Peak demand in last May, and on decreasing trend even after take into account surge in covid case + banning topglove from entry to US since july
https://importkey.com/i/supermax-healthcare-inc
Remark: US is largest import market and US market command highest ASP premium if compared to any other country.
Stock
2020-09-07 13:20 | Report Abuse
US is top 4 largest glove maker in Msia. Top glove export about 25% volume to US market, but, US have ban topglove export since July. Although other country can fill up demand, but US market command highest ASP premium if compared to any other country.
Glove export to US on decreasing trend. Take supermax healthcare data, The US market peak demand already reached in May, thereafter, already on decreasing demand from supermax.
https://importkey.com/i/supermax-healthcare-inc
Stock
2020-09-07 13:16 | Report Abuse
US is supermax largest export market and US market command highest ASP premium if compared to any other country.
Glove export to US on decreasing trend. The US market peak demand already reached in May, thereafter, already on decreasing demand from supermax.
https://importkey.com/i/supermax-healthcare-inc
News & Blogs
2020-09-07 12:32 | Report Abuse
Glove export to US on decreasing trend
https://importkey.com/i/supermax-healthcare-inc
Stock
Stock
2020-09-04 15:41 | Report Abuse
US second stimulus package is ready to present by 12 Sept, printing more money to stimulus US economy, boost economy activity, stimulus gasoline demand
Stock
2020-09-04 15:25 | Report Abuse
CPO price still above RM 2900
Stock
2020-09-04 11:49 | Report Abuse
Carimin is NET CASH company, about half of the current price is back by CASH hoard.
US second stimulus package by 12 Sept + vaccine available as early Oct in US = crude oil price to CONTINUE recover back.
Stock
2020-09-03 21:38 | Report Abuse
Initial jobless claims, week ended Aug. 29: 881,000 vs. 950,000 expected
Continuing claims, week ended Aug. 22: 13.254 million vs. 14.000 million expected
By 12 Sept, US second stimulus packager will announce, boosting further recovery economy + vaccine ready as early as next month = demand US gasoline will increasing
Stock
2020-09-03 21:23 | Report Abuse
US second stimulus package + vaccine available as early Oct in US = crude oil price to recover back.
Brent crude oil have recover from as low as USD 30 to current level USD 43-46. These is more than 40% recover. Hibiscus selling crude oil on average USD 31 in its latest Q result.
As show in chart, Brent crude oil major resistance level is at USD46, it have many attempt to break through these level, retrace back now to support level USD 43. It’s still range bound trading, awaiting major catalyst, US second stimulus by 12 Sept.
Stock
2020-09-03 21:23 | Report Abuse
US second stimulus package + vaccine available as early Oct in US = crude oil price to recover back.
Brent crude oil have recover from as low as USD 30 to current level USD 43-46. These is more than 40% recover. Hibiscus selling crude oil on average USD 31 in its latest Q result. As show in chart, Brent crude oil major resistance level is at USD46, it have many attempt to break through these level, retrace back now to support level USD 43. It’s still range bound trading, awaiting major catalyst, US second stimulus by 12 Sept.
Stock
2020-09-03 21:13 | Report Abuse
Hibiscus crude oil selling price is USA 31.8 in previous Q result.
The curent brent crude oil market price is USD 43-46, these is a massive increment above 40%. As cost is relatively fixed, any surplus above cost is PURE PROFIT
Hibiscus just announce get award 3 new producing oil block in UK, capacity expansion forward
Stock
2020-09-03 17:29 | Report Abuse
Inside China's new lab conducting late-stage Covid-19 vaccine trials
CNN's David Culver takes us inside a brand new vaccine lab in China and speaks to scientists there about how close they are to a coronavirus vaccine.
https://youtu.be/N8a2RZqpeTE
Stock
2020-09-03 17:28 | Report Abuse
Inside China's new lab conducting late-stage Covid-19 vaccine trials
CNN's David Culver takes us inside a brand new vaccine lab in China and speaks to scientists there about how close they are to a coronavirus vaccine.
https://youtu.be/N8a2RZqpeTE
Stock
2020-09-03 16:24 | Report Abuse
US already confrim to get vaccine as early as next month, OCT. Vaccine is OPPOSITE correlate with glove
https://www.theedgemarkets.com/article/us-cdc-tells-states-prep-covid19-vaccine-distribution-nov
Stock
2020-09-03 16:23 | Report Abuse
US already confrim to get vaccine as early as next month, OCT. Vaccine is OPPOSITE correlate with glove
https://www.theedgemarkets.com/article/us-cdc-tells-states-prep-covid19-vaccine-distribution-nov
Stock
2020-09-03 16:21 | Report Abuse
ahpooki2
Local pharma profit margin on vaccine is small as it is patent for production.
Stock
2020-09-03 16:18 | Report Abuse
US CDC tells states to prep for Covid-19 vaccine distribution by November
September 03, 2020 06:49 am +08
(Sept 3): The U.S. Centers for Disease Control and Prevention (CDC) has asked state public health officials to prepare to distribute a potential coronavirus vaccine to high-risk groups as soon as late October or early November, documents published by the agency showed on Wednesday.
The timing of release of any vaccine has taken on political importance as U.S. President Donald Trump seeks re-election in November, after putting substantial federal resources into vaccine development.
"For the purpose of initial planning, CDC provided states with certain planning assumptions as they work on state specific plans for vaccine distribution, including possibly having limited quantities of vaccines in October and November," a CDC spokeswoman told Reuters.
The New York Times had earlier reported that the CDC had contacted officials in all 50 states and five large cities with the documents.
The country's top infectious disease expert Anthony Fauci earlier on Wednesday said on MSNBC that based on the patient enrollment rate in COVID-19 vaccine trials underway, there could be enough clinical data to know by November or December that one of the vaccines is safe and effective.
The documents put online by the New York Times showed that the CDC is preparing for one or two vaccines for COVID -19 to be available in limited doses as soon as late October.
The vaccines may be available free of cost first to high-risk groups including health care works, national security personnel, residents and staff at COVID-19 long-term care facilities, the agency said in the documents.
Drug developers including Moderna Inc, AstraZeneca Plc and Pfizer Inc are leading the race to develop a safe and effective vaccine for the respiratory illness.
The documents describe two vaccine candidates that must be stored at temperatures of -70 and -20 degrees centigrade. Those storage requirements match profiles of candidates from Pfizer and Moderna.
https://www.theedgemarkets.com/article/us-cdc-tells-states-prep-covid19-vaccine-distribution-nov
Stock
2020-09-03 16:17 | Report Abuse
US CDC tells states to prep for Covid-19 vaccine distribution by November
September 03, 2020 06:49 am +08
(Sept 3): The U.S. Centers for Disease Control and Prevention (CDC) has asked state public health officials to prepare to distribute a potential coronavirus vaccine to high-risk groups as soon as late October or early November, documents published by the agency showed on Wednesday.
The timing of release of any vaccine has taken on political importance as U.S. President Donald Trump seeks re-election in November, after putting substantial federal resources into vaccine development.
"For the purpose of initial planning, CDC provided states with certain planning assumptions as they work on state specific plans for vaccine distribution, including possibly having limited quantities of vaccines in October and November," a CDC spokeswoman told Reuters.
The New York Times had earlier reported that the CDC had contacted officials in all 50 states and five large cities with the documents.
The country's top infectious disease expert Anthony Fauci earlier on Wednesday said on MSNBC that based on the patient enrollment rate in COVID-19 vaccine trials underway, there could be enough clinical data to know by November or December that one of the vaccines is safe and effective.
The documents put online by the New York Times showed that the CDC is preparing for one or two vaccines for COVID -19 to be available in limited doses as soon as late October.
The vaccines may be available free of cost first to high-risk groups including health care works, national security personnel, residents and staff at COVID-19 long-term care facilities, the agency said in the documents.
Drug developers including Moderna Inc, AstraZeneca Plc and Pfizer Inc are leading the race to develop a safe and effective vaccine for the respiratory illness.
The documents describe two vaccine candidates that must be stored at temperatures of -70 and -20 degrees centigrade. Those storage requirements match profiles of candidates from Pfizer and Moderna.
https://www.theedgemarkets.com/article/us-cdc-tells-states-prep-covid19-vaccine-distribution-nov
Stock
Stock
2020-09-03 10:46 | Report Abuse
bought carimin at 63-63.5sen
Stock
2020-09-03 10:40 | Report Abuse
bought IWCITY at 58.5-59sen
Stock
Stock
2020-09-02 10:48 | Report Abuse
sustain above RM 1.36 is crucial for trend REVERSAL
Stock
2020-09-02 10:19 | Report Abuse
Pchemcial is good proxy for Petronas, benefited from recovery in crude oil. Strong balance sheet with net cash position + dividend policy 55% offer limited downside risk.
Stock
2020-09-02 10:16 | Report Abuse
LCtitan expansion in Indonesia is timely, benefited from Indonesia currency strengthen against USD.
Stock
2020-09-02 10:15 | Report Abuse
Immediate resistance level at 1.36. Once IJM successful breakthrough these level, reversal trend is confirm, on track back to recover above RM 1.60
Stock
2020-09-02 10:07 | Report Abuse
Current weakness in USD is good for LCtitan, as all its feedstock are USD denominated, but product sale is local currency denominated, mainly in Msia, China, Indonesia.
Stock
Stock
Stock
2020-09-01 21:12 | Report Abuse
Director buy ijm
Top Biggest shareholder, EPF buy ijm
Second biggest shareholder, kWP buy ijm
Stock
Stock
2020-09-01 10:46 | Report Abuse
Jtiasa is BEST proxy for CPO price recovery.. All it’s planted palm oil already in PRIME MATURITY, CPO production volume increase with better CPO price above. RM 2800 = windfall profit for Jtiasa
Stock
2020-09-01 10:42 | Report Abuse
Brent crude oil recovery will spur up petrochemical recovery from better profit margin forward.
Stock
2020-09-01 10:35 | Report Abuse
IJM, a blue chip stock for exposure to construction + property + plantation + port concession + toll concession.
Stock
Stock
2020-08-28 20:07 | Report Abuse
first interim dividend 2 sen
Stock
2020-08-28 19:53 | Report Abuse
IJM already commence share buyback today, total 10 million share buyback today
Stock
2020-08-28 19:51 | Report Abuse
share dividend 1 for 16, equivalent to 4.3sen, yield 6.25%,
Stock: [TOPGLOV]: TOP GLOVE CORPORATION BHD
2020-09-07 18:29 | Report Abuse
Recent Fundamental change in topglove
1. Currency exchange, USD have weakness from 4.3 in to current 4.15
2. Feedstock cost increase, synthetic rubber price hike due to shortage.
3. Labor cost increase, salary, accommodation and reimbursement
4. Banning export to US, the largest market since July, sales volume unable to realize, re route sales involve logistic cost
5. Banning export to US, loss highest profit margin market as US command premium selling price.